Brentuximab-based chemotherapy improves survival and reduces toxicity in patients with advanced Hodgkin lymphoma
1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2. Progression-free survival at 48 months was significantly greater in ...









![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg)
